Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study
https://doi.org/10.17650/1818-8346-2008-0-1-2-39-46
Abstract
Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell lymphocytic leukemia were the main goals of this retrospective study. It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity.
About the Authors
Ye. А. Stadnik
Городская клиническая больница №31
Russian Federation
Russian Federation
Ye. А. Nikitin
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
B. V. Biderman
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
G. N. Salogub
Городская клиническая больница №31
Russian Federation
Russian Federation
Yu. Yu. Lorie
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
N. N. Tsyba
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
Yu. A. Alexeeva
Городская клиническая больница №31
Russian Federation
Russian Federation
V. A. Doronin
Центральная клиническая больница №2 Министерства путей сообщения
Russian Federation
Russian Federation
V. N. Mashuk
Краснодарский краевой онкодиспансер
Russian Federation
Russian Federation
R. I. Vabishevich
Федеральный центр крови, сердца и эндокринологии им. акад. В.А. Алмазова
Russian Federation
Russian Federation
A. L. Melikyan
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
T. I. Kolosheinova
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
L. Yu. Kolosova
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
A. B. Sudarikov
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
L. G. Kovaleva
ГУ «Гематологический научный центр» РАМН
Russian Federation
Russian Federation
A. Yu. Zaritsky
Федеральный центр крови, сердца и эндокринологии им. акад. В.А. Алмазова
Russian Federation
Russian Federation
References
1. Catovsky D., Richards S., Matutes E. et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370(9583):230—9.
2. Eichhorst B.F., Busch R., Hopfinger G. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885—91.
3. McLaughlin P., Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998,16:2825—33.
4. Huhn D., von Schilling C., Wilhelm M. et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326—31.
5. Manshouri T., Do K.A., Wang X. et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507—13.
6. O'Brien S.M., Kantarjian H., Thomas D.A. et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19(8):2165—70.
7. Di Gaetano N., Xiao Y., Erba E. et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114(4):800—9.
8. Alas S., Bonavida B., Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961—6.
9. Demidem A., Lam T., Alas S. et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177—86.
10. Byrd J.C., Peterson B.L., Morrison V.A. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101(1):6—14.
11. Keating M.J., O'Brien S., Albitar M. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079—88.
12. Wierda W., O'Brien S., Wen S. et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4070—8.
13. Rummel M.J., Stilgenbauer S., Gamm H. et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL)- preliminary results of a randomised phase- III multicenter study. Blood 2002;100(11):384a, abstr 1489.
14. O'Brien S., Kantarjian H., Beran M. et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 1993;82:1695700.
15. Bosch F., Perales M., Cobo F. et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). Blood 1997;90(Suppl 1):530a, abstr 2360.
16. Tsimberidou A.M., Keating M.J., Giles F.J. et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 2004;100(12):2583—91.
17. Byrd J.C., Rai K., Peterson B.L. et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105(1):49—53.
18. Cheson B.D. Bennett J.M. et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990—7.
19. Никитин Е.А., Пивник А.В., Судариков А.Б. и др. Сравнение форм хронического лимфолейкоза в зависимости от мутационного статуса генов вариабельного региона иммуноглобулинов. Тер арх 2000;72(7):52—6.
20. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31—41.
21. Keating M.J., O’Brien S., Lerner S. et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165—71.
Review
For citations:
Stadnik Ye.А., Nikitin Ye.А., Biderman B.V., Salogub G.N., Lorie Yu.Yu., Tsyba N.N., Alexeeva Yu.A., Doronin V.A., Mashuk V.N., Vabishevich R.I., Melikyan A.L., Kolosheinova T.I., Kolosova L.Yu., Sudarikov A.B., Kovaleva L.G., Zaritsky A.Yu. Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study. Oncohematology. 2008;(1-2):39-46. (In Russ.) https://doi.org/10.17650/1818-8346-2008-0-1-2-39-46
Views:
152
Email this article 